Resmetirom (Free Base) | 920509-32-6 | MGL-3196, VIA-3196 | Liver-Targeted THR-β Agonist

Resmetirom More Info

Resmetirom, also known by its developmental code MGL-3196, is a first-in-class, orally administered, small molecule thyroid hormone receptor-beta (THR-β) agonist . Chemically designated as 2-[3,5-dichloro-4-[(6-oxo-5-propan-2-yl-1H-pyridazin-3-yl)oxy]phenyl]-3,5-dioxo-1,2,4-triazine-6-carbonitrile, it has the molecular formula C₁₇H₁₂Cl₂N₆O₄ and a molecular weight of approximately 435.2 g/mol . Marketed under the brand name Rezdiffra®, resmetirom was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in March 2024 for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, corresponding to stages F2 to F3 . This approval marked a significant milestone as the first pharmacologic therapy specifically indicated for this progressive liver disease.

The primary mechanism of action of resmetirom involves selective agonism of the thyroid hormone receptor beta isoform (THR-β), which is the predominant thyroid hormone receptor expressed in the liver . Unlike the alpha isoform (THR-α) that mediates thyroid hormone effects in cardiac and bone tissues, THR-β activation in the liver promotes hepatic fat catabolism and reduces lipotoxicity. Resmetirom demonstrates 83.8% efficacy relative to the endogenous ligand triiodothyronine (T3) for THR-β activation with an EC₅₀ of 0.21 µM, while showing only 48.6% efficacy for THR-α with a substantially higher EC₅₀ of 3.74 µM, thus providing approximately 28-fold selectivity for the beta isoform . This selectivity is critical for minimizing extrahepatic thyroid hormone-related adverse effects.

The downstream effects of resmetirom on liver metabolism are multifaceted. Upon entering hepatocytes via the organic anion transporting polypeptide 1B1 (OATP1B1), resmetirom heterodimerizes with the retinoid X receptor (RXR) and interacts with thyroid hormone response elements (TREs) in target gene regulatory regions . This transcriptional activation upregulates genes involved in mitochondrial biogenesis, fatty acid β-oxidation, and lipophagy, while concurrently downregulating genes mediating lipid droplet assembly. The net effect is a reduction in intrahepatic triglyceride content and mitigation of lipotoxicity. Additionally, resmetirom facilitates hepatic low-density lipoprotein cholesterol (LDL-C) uptake and conversion of cholesterol to bile acids, thereby lowering atherogenic lipid levels in the circulation . The compound also transcriptionally upregulates iodothyronine deiodinase 1 (DIO1), which promotes conversion of thyroxine (T4) to T3, addressing the intrahepatic hypothyroid state induced by lipotoxicity.

Clinical efficacy of resmetirom has been established primarily through the phase 3 MAESTRO-NASH trial, a 54-month randomized, double-blind, placebo-controlled study in patients with biopsy-confirmed MASH and liver fibrosis . The trial met its primary endpoints at 52 weeks, demonstrating both MASH resolution without worsening of fibrosis and at least one-stage improvement in fibrosis without worsening of MASH . Secondary analyses have shown that concomitant weight loss of 5% or more enhances resmetirom's efficacy, with MASH resolution rates of 56.6% in patients achieving weight loss compared to 33.8% in those without significant weight loss, when treated with the 100 mg dose . Importantly, the efficacy of resmetirom was not impacted by background treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2i), supporting its use in patients with type 2 diabetes mellitus .

The safety profile of resmetirom is generally favorable but requires awareness of specific adverse effects and drug interactions. Meta-analyses of randomized controlled trials have shown that the pooled risk ratio for serious adverse events is 0.85 (95% CI: 0.63–1.14), indicating no significant difference compared to placebo . However, resmetirom is associated with increased incidences of gastrointestinal events, particularly diarrhea (risk ratio 1.82) and nausea (risk ratio 1.73) . The FDA prescribing information carries warnings for hepatotoxicity, requiring monitoring of liver tests during treatment, and for gallbladder-related adverse reactions including cholelithiasis and cholecystitis . Pharmacokinetically, resmetirom has an elimination half-life of approximately 4.6 hours in beagle dog models, with peak plasma concentrations achieved around 3.3 hours after oral administration . The compound is metabolized primarily by CYP2C8, and concomitant use with strong or moderate CYP2C8 inhibitors is either not recommended or requires dose adjustment . Due to its high plasma protein binding (>99%), the amount transferred into breast milk is likely low, though limited data exist regarding use during pregnancy or lactation .

Package Image

FAQ

Q1. Can I get a free sample?

We can send you a samll free sample, and you only need to pay for the shipping cost.

Q2. What is the HyperChem payment term?

T/T in advance
LC at sight
DP at sight

Bank transfer

PayPal

Bitcoin...

Q3. What is HyperChem shipment policy?

Our policy is to strive for the quickest shipment time possible.

For ready stock samples, they are usually shipped within 3 working days after payment received.
For non-ready stock, please contact HyperChem sales team to negotiate.

Q4. What is HyperChem shipment term?

By Express  
FedEx  UPS  DHL  EMS                               
Fast: 3-7 days around, high cost, door to door service

By Air                                        
Suitable for more than 50kg 
Fast: 3-7 days, hight cost, port to port, professional broker needed 

By Sea
Suitable for more than 500kg      
Fast: 7-45 days, low cost, port to port, professional broker needed 

We will always attempt to utilize the quickest and most affordable way for customers to receive orders. And follow -up with customers via email for all shipment details as well as updated track information until it arrives without damage.

Q5. What HyperChem will provide after shipment?

For sample orders: 
After shipment is done, an timely email including:

1. Track details (Fedex /TNT/DHL/EMS Track number)
2. Packaging photo
3. COA, MSDS, etc
4. Dispatch date & Estimated arriving time
5. Shipping invoice

For commercial orders
A full set of shipment documents as well as package photos can be provided in scan-copy and original, to help customers complete the customs clearance process.

Company Profile

Established in 2013, Hyper Chem has exclusive tie-ups with leading manufacturers, supplying raw materials produced in GMP and ISO 9002 certified facilities, and provides high-quality ingredients and raw materials to cater to the requirements of our diverse range of clients.

Among them, our key client industrial sectors around the global are:

Pharmaceuticals
Nutrition Ingredients/ Dietary supplements
Cosmetic Ingredients
Food Ingredients
Veterinary API
Agriculture fertilizer
Custom Synthesis lab supply

HyperChem provides to its wonderful and honorable clients comprehensive purchasing and distribution services which ensure that we are delivering the right generic, raw, or customized product, make sure that we are delivering it at the right time, ensure that it is delivered in the specified amount, and in the right kind of packaging to clients and customers of all types of industries irrespective of their size of operation.